← Back to all trials
Recruiting
NCT07081217
Radiocaine Safety Study
Conditions: Healthy Subjects
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: Yes
Phase: EARLY_PHASE1
Enrollment: 6
Sponsor: Lutroo Imaging LLC
Location: Stanford University School of Medicine Stanford California
Summary
This is a Phase 1, single-center, open-label study evaluating the safety, biodistribution, and radiation dosimetry of Radiocaine™, an investigational fluorine-18-labeled PET radiotracer designed to bind voltage-gated sodium channels. The study enrolls adult volunteers and aims to inform future clinical development in molecular imaging applications. Radiocaine™ is being developed as a potential diagnostic imaging agent and imaging biomarker for the localization and quantification of sodium channel activity.
Eligibility Criteria
Inclusion Criteria:
* 18 years and older
* Able to provide written consent
* Willing and able to undergo ECG, imaging, blood sampling, and complete self-assessment rating scales at the specified time points
* Willing and able to participate in all imaging procedures and complete the self-assessment rating scales at the specified time points
Exclusion Criteria:
* Body mass index (BMI) of 32 or greater, weight \>300 lbs
* Diagnosis of severe depression/anxiety (PROMIS score \> 95%) or suicidal ideation
* History of opioid abuse or opioid use disorder
* History of seizures or epilepsy
* History of major Axis I or Axis II psychiatric disorder that might, in the opinion of the investigator, make it difficult for the subject to complete all the procedures (e.g. obsessive-compulsive disorder, bipolar disorder, schizophrenia, or schizoaffective disorder)
* History of cardiac arrhythmia
* History of major orthopedic surgery within the last 12 months
* Recent history (previous 6 months) of sodium channel blocker use, including, but not limited to: carbamazepine, lamotrigine, lidocaine, phenytoin, propranolol, or valproate
* Any significant systemic illness or medical condition that could lead to difficulty complying with the study protocol
* Creatinine clearance (calculated using the Cockcroft-Gault formula or measured) \< 60 mL/min or serum creatinine \>1.5 x ULN
* QTcF \>470 msec for females and QTcF \>450 msec for males on screening ECG
* MRI-incompatible implants, large tattoos, previous shrapnel injury
* Pregnancy or lactating
* History of contact sport participation, such as football, hockey, or rugby
* Known claustrophobia related to MR or PET-MRI scanners
* Recent blood donation/draw of \>1 unit (previous 4 weeks)
* History of hypersensitivity to local anesthetics of the amide type
* Family or personal history of familial malignant hyperthermia
Source: ClinicalTrials.gov (NCT07081217). StuddyBuddy aggregates publicly available trial information.